Last reviewed · How we verify
CBD, synthetic form
CBD, synthetic form is a Small molecule drug developed by CannaMore Biotechs. It is currently in Phase 2 development for Treatment-resistant epilepsy, Multiple sclerosis spasticity.
CBD, a synthetic form, interacts with the body's endocannabinoid system to produce therapeutic effects.
A synthetic form of cannabidiol (CBD) is being studied as a potential treatment for various conditions, including Steroid Dependent Crohn's Disease, Ulcerative Colitis, Opioid Use Disorder, Alexithymia, and HIV. Clinical trials are evaluating the safety, tolerability, and efficacy of this synthetic CBD in comparison to a placebo.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | CBD, synthetic form |
|---|---|
| Sponsor | CannaMore Biotechs |
| Target | CB1 and CB2 receptors |
| Modality | Small molecule |
| Therapeutic area | Pain management, Anxiety disorders |
| Phase | Phase 2 |
Mechanism of action
The synthetic CBD binds to cannabinoid receptors in the body, influencing various physiological processes. This interaction can lead to reduced inflammation, improved mood, and other therapeutic benefits.
Approved indications
- Treatment-resistant epilepsy
- Multiple sclerosis spasticity
Common side effects
- Dizziness
- Nausea
- Fatigue
Key clinical trials
- Dronabinol and Epidiolex to Manage Uncontrolled Residual Symptoms of Buprenorphine Initiation Trial (PHASE3)
- Role of CBD in Improving Alexithymia (PHASE2)
- A Phase 2a Study to Evaluate the Safety, Tolerability and Efficacy of Cannabidiol as a Steroid-sparing Therapy in Steroid-dependent Crohn's Disease Patients (PHASE2)
- Phase 2a Study to Evaluate IcBD-01 Enema in Active Ulcerative Colitis Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CBD, synthetic form CI brief — competitive landscape report
- CBD, synthetic form updates RSS · CI watch RSS
- CannaMore Biotechs portfolio CI
Frequently asked questions about CBD, synthetic form
What is CBD, synthetic form?
How does CBD, synthetic form work?
What is CBD, synthetic form used for?
Who makes CBD, synthetic form?
What development phase is CBD, synthetic form in?
What are the side effects of CBD, synthetic form?
What does CBD, synthetic form target?
Related
- Target: All drugs targeting CB1 and CB2 receptors
- Manufacturer: CannaMore Biotechs — full pipeline
- Therapeutic area: All drugs in Pain management, Anxiety disorders
- Indication: Drugs for Treatment-resistant epilepsy
- Indication: Drugs for Multiple sclerosis spasticity
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing